New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2012
06:14 EDTJNJ, BCS, DB, LYG, STD, JPM, DOW, AEG, RY, ING, RIMM, CS, UBS, BBVA, RBSOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Europe's program to defuse its financial crisis by injecting cash into the banking system is running out of energy as interest rates rise and some banks have little cash left, the Wall Street Journal reports...Dow Chemical (DOW) and other chemical companies see new opportunities in the enormous domestic deposits of gas, the Wall Street Journal reports...REUTERS: U.S. coal exports to China could more than double to over 12M tons in 2012 due to depressed freight rates and a decline in U.S. demand, says Xcoal Energy & Resources CEO Thrasher, Reuters reports...Johnson & Johnson (JNJ) received EU clearance to purchase Swiss medical device maker Synthes for about $21B, Reuters reports...BLOOMBERG: Research In Motion (RIMM) is close to deciding on a financial adviser, and JPMorgan Chase (JPM) is said to be the leading candidate to help the company weigh strategy options, Bloomberg reports.
News For STD;RBS;ING;LYG;BBVA;RY;DB;UBS;AEG;BCS;CS;DOW;JNJ;RIMM;JPM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 10, 2014
11:03 EDTJPMJPMorgan drops 2% after CFO talks down Q4 numbers
Subscribe for More Information
08:45 EDTRBSRBS to exit bond trading in Japan, WSJ reports
Royal Bank of Scotland Group plans to give up its primary dealership in the Japanese government bond market early next year as part of the bank’s strategy to scale back its fixed-income businesses due to increasing regulatory costs, said The Wall Street Journal, citing a person familiar with the matter. The move will likely result in "sizable" job cuts, the report added. Reference Link
07:56 EDTDOWUBS to hold a conference
Agriculture Investor Day is being held in Chicago on December 10.
06:17 EDTJPMJPMorgan faces $22B capital hole under new Fed rules, Financial Times says
Subscribe for More Information
December 9, 2014
16:00 EDTDOWOptions Update; December 9, 2014
Subscribe for More Information
14:57 EDTJPMFed to propose rulemaking on risk-based capital surcharges for GSIB banks
Subscribe for More Information
14:42 EDTJPMFed sees setting capital surcharge up to 4.5% for big U.S. banks, Bloomberg says
Bloomberg cites surcharge estimates in Federal Reserve staff memo. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
15:26 EDTDBDeutsche Bank sued by U.S. over alleged scheme to avoid income taxes
Subscribe for More Information
15:10 EDTDBDOJ files suit against Deutsche Bank over income tax avoidance, Bloomberg says
Subscribe for More Information
10:00 EDTDBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:40 EDTDBDeutsche Bank and Cisco to host a conference call
Subscribe for More Information
07:56 EDTRBS, CSRBS asks Credit Suisse, others for Coutts bids by Christmas, Reuters says
Subscribe for More Information
06:35 EDTJPMValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:21 EDTJPM, BCSDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
06:00 EDTDBDeutsche Bank downgraded to Underperform from Market Perform at Keefe Bruyette
Subscribe for More Information
December 7, 2014
18:31 EDTCSCredit Suisse assesses prime brokerage business, Reuters says
Subscribe for More Information
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use